CGNT Earnings Date: Dec 8, 2026 (Estimated) — Cognyte Software Ltd.
NASDAQ · Technology · Software - Infrastructure
Updated
When is CGNT's next earnings date?
Cognyte Software Ltd. (CGNT) is expected to report Q3 2027 earnings on Tuesday, December 8, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.13 on revenue of $113.4M.
How did CGNT do in its last earnings report?
In its most recent report on Sep 9, 2026 (Q2 2027), Cognyte Software Ltd. posted EPS of $0.15 versus the $0.09 estimate, a beat of 114.3%. Revenue was $109.2M against a $108.5M estimate. The stock's 1-day post-earnings move was -1.0%.
How much does CGNT stock move after earnings?
CGNT beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.9% (up or down) in the day after earnings.
About Cognyte Software Ltd.
Cognyte Software Ltd., established in Herzliya, Israel, in 2020, delivers sophisticated investigative analytics software to a global array of governmental organizations and commercial businesses. Its flagship offering, branded "Actionable Intelligence for a Safer World," is an open-source platform specifically engineered to expedite and bolster the efficacy of investigations. The company's diverse portfolio of solutions includes advanced analytics for network intelligence, open source and threat intelligence, and operational intelligence. These versatile tools are crafted to address a wide variety of scenarios and serve an extensive user base, from data analysts and investigation managers to security operations center operators and field teams. Furthermore, Cognyte offers crucial supplementary services such as customer support, professional guidance, and integration assistance. Its clientele spans national, regional, and local government bodies, alongside commercial entities and physical security firms.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 | Q2 2027 | 0.09 | 0.15 | +114.29% | $109.2M | ✅ Beat | -0.97% | +3.04% | +5.95% |
| 2026-06-03 | Q1 2027 | 0.07 | 0.03 | -57.14% | $105.5M | ❌ Miss | -20.57% | -23.32% | -22.63% |
| 2026-03-25 | Q4 2026 | -0.02 | 0.10 | +600.00% | $106.2M | ✅ Beat | +7.23% | +2.79% | +19.92% |
| 2025-12-09 | Q3 2026 | -0.04 | 0.03 | +175.00% | $100.7M | ✅ Beat | +8.36% | +6.02% | +6.58% |
| 2025-09-09 | Q2 2026 | 0.03 | 0.08 | +166.67% | $97.5M | ✅ Beat | -11.33% | -11.23% | -11.33% |
| 2025-04-02 | Q4 2025 | 0.01 | 0.03 | +200.00% | $94.5M | ✅ Beat | +21.05% | +6.45% | +19.83% |
| 2024-12-11 | Q3 2025 | -0.04 | 0.02 | +150.00% | $89.0M | ✅ Beat | -4.64% | +7.42% | -1.28% |
| 2024-09-10 | Q2 2025 | -0.02 | 0.05 | +350.00% | $84.4M | ✅ Beat | -13.04% | -9.81% | -11.16% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY14 · $3.7M total
| Segment | Share | Revenue | YoY | Q3 FY13 | Q1 FY14 | Q2 FY14 |
|---|---|---|---|---|---|---|
| Medical | 82.9% | $3.0M | +21.4% | $2.7M | $3.4M | $3.0M |
| Industrial | 17.1% | $623K | -30.8% | $1.0M | $760K | $623K |
By region
FY2026 · $780.5M total · annual
| Segment | Share | Revenue | YoY | FY2018 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|
| EMEA | 45.7% | $356.9M | — | — | — | — | — |
| ISRAEL | 35.8% | $279.1M | +14.9% | — | $274.1M | $328.4M | $201.6M |
| GERMANY | 7.4% | $58.0M | +7.4% | — | $86.8M | $63.3M | $44.5M |
| Americas | 3.0% | $23.6M | — | — | — | — | — |
| Other EMEA Region | 2.5% | $19.8M | +4.1% | — | $18.7M | $14.1M | $13.2M |
| Asia Pacific | 2.5% | $19.6M | +41.5% | — | $11.9M | $12.7M | $7.6M |
| UNITED STATES | 1.9% | $15.2M | +6.5% | — | $44.7M | $37.7M | $35.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.